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 ENANTIOSELECTIVE SYNTHESIS OF DUAL 5-HT4/5-HT3 
SEROTONERGIC AZANORADAMANTANE SC-52491 
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Clara I. Villamil a, Daniel L. Flynn2 
 
Department of Medicinal Chemistry, Searle Research & Development, 
a4901 Searle Parkway, Skokie, IL 60077 
b700 Chesterfield Village Parkway, St. Louis, MO  63198 
 
 
Abstract: A racemic synthesis of azanoradamantane (±)-3 was accomplished via 
Yamamoto’s MAD-catalyzed Diels-Alder protocol.  Subsequently, a scalable asymmetric 
synthesis of azanoradamantane benzamide SC-52491 was carried out employing 
Helmchen's asymmetric Diels-Alder methodology to construct all four contiguous 
asymmetric centers with the correct relative stereochemistry and in 99.3% e.e.   
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Pharmaceutical companies are advancing an increasing number of enantiomerically pure drugs1 in order 
to maximize potency and selectivity, and to eliminate the complications which may arise from the presence of a 
less active or inactive stereoisomer.  The asymmetric Diels-Alder2 reaction is a powerful synthetic method for 
the construction of  non-racemic pharmacologically active agents.  
In earlier communications3 we disclosed a series of azaadamantane and azanoradamantane benzamides, 
including the potent serotonin 5-HT4 agonist/5-HT4 antagonist SC-52491, which has an EC50 of 51 nM in the 5-
HT4 tunica muscularis mucosae assay
4
 and a Ki of 1.2 nM at the 5-HT3 receptor.
5
  SC-52491 was chosen for 
further study of its gastrointestinal prokinetic activity and its antiemetic activity based on its potent 5-HT4 
agonism and its tandem property of potent 5-HT3 antagonism, respectively, combined with its exceptional 
selectivity versus other monoamine receptors.6  It is orally active and exhibits potent prokinetic activity and 
antiemetic activity in vivo, and compares very favorably with the marketed prokinetic cisapride. SC-52491 is 
the more active enantiomer with respect to both 5-HT4 and 5-HT3 activity, as it is 70X as potent as SC-52490 in 
the functional 5-HT4 assay, and it is 3X as potent in its binding to the 5-HT3 receptor. 
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We required a scalable asymmetric synthesis of SC-52491, which contains four contiguous asymmetric 
centers.  Our previous7 synthetic route (Scheme 1) employed a reductive Pauson-Khand reaction8 which was 
ideal for small-scale synthesis, and a late-stage resolution which provided us with both enantiomers for 
biological evaluation, but these procedures are not easily scalable.  The previous synthesis of SC-52491 did 
employ a very efficient closure to the azanoradamantane ring system [(-)-1 to (+)-2], and we hoped that we 
could utilize a similar cyclization in our new synthetic strategy.  We also wanted to eliminate chlorinated 
solvents from the synthesis and to simplify or eliminate any chromatographic purifications. 
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Scheme 1 
 
 
We envisioned a new approach based on the retrosynthetic analysis shown in Scheme 2, wherein the 
azanoradamantane 3 would be formed in one step from a tetrasubstituted cyclopentane 4 via a tandem 
cyclization involving SN2 displacement of suitable leaving groups (X) by the primary amine.  One of the two 
cyclizations is the same as the efficient cyclization employed in our previous synthetic approach.  The 
tetrasubstituted cyclopentane 4 would then be derived from oxidative cleavage of a rigid norbornene 5, in which 
the four contiguous asymmetric centers could be easily defined and prepared via an asymmetric Diels-Alder 
reaction. 
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Scheme 2 
 
We first employed Yamamoto's MAD-catalyzed Diels-Alder reaction9 to prepare norbornene (±)-7 
(Scheme 3).  This approach assembles the four requisite stereocenters in their proper relative orientation, albeit 
in racemic fashion.  We originally hoped to employ an early-stage resolution or to employ a chiral Lewis acid 
catalyst in the Diels-Alder reaction to obtain the correct absolute configuration of the four stereocenters.  
Ultimately the Yamamoto approach allowed us to explore various means of installing functionality to provide 
the bridgehead nitrogen and the amino substituent of aminoazanoradamantane 3.  As per Yamamoto’s protocol, 
cyclopentadiene is reacted with tert-butyl methyl fumarate 610 with MAD catalysis to afford the Diels-Alder 
adduct (±)-7 in high yield and excellent diastereoselectivity (98:2).  The esters are easily differentiated by 
cleaving the tert-butyl ester with trifluoroacetic acid to afford carboxylic acid (±)-7.  We proceeded from 
Yamamoto’s intermediate (±)-7 with a Curtius rearrangement to install the exo-amino substituent protected as 
the benzyl carbamate in compound (±)-8.  Lithium borohydride reduction gave the endo hydroxymethyl 
derivative (±)-9. 
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Scheme 3 
 
 
The alcohol (±)-9 was converted to the mesylate (±)-10 in quantitative yield, but the mesylate was 
unexpectedly resistant toward displacement by azide.   Treatment with sodium azide in a variety of solvents, 
with or without added sodium iodide present in the reaction mixture gave no desired product.  Only starting 
material was observed until the temperature was raised sufficiently for consumption of starting material, at 
which point the norbornene bicyclic system was also destroyed,  presumably via a retro-Diels-Alder reaction.  
To overcome this problem, alcohol (±)-9 was oxidized to the aldehyde (±)-12 in 95% yield with no evidence of 
epimerization.  Reductive amination of the aldehyde with ammonium acetate gave the desired primary amine 
(±)-13, but in consistently low yields, along with significant quantities of secondary amine by-product.  
Attempts to optimize the reductive amination of aldehyde (±)-12 were unsuccessful.  The amine (±)-13 was 
protected as the BOC derivative (±)-14.  Despite the inefficient reductive amination, sufficient quantities of the 
BOC-protected amine (±)-14 were obtained to continue validation of the Diels-Alder approach to 
aminoazanoradamantanes. 
Ozonolysis of the norbornene (±)-14 followed by workup with sodium borohydride gave the diol (±)-15 
in 27 % yield (Scheme 4).  Diol (±)-15 was converted to the azanoradamantane (±)-16 by a sequence involving 
bis-tosylation, trifluoroacetic acid removal of the BOC protecting group, and subsequent treatment with 
diisopropylethylamine, as in the conversion of (-)-1 to (+)-2.  We were confident at this point that we had 
obtained the desired azanoradamantane based on spectroscopic analysis, but final confirmation was provided by 
reductive removal of the benzyl carbamate protecting group to afford the free aminoazanoradamantane (±)-3, 
which was identical by proton NMR to the chiral material we had obtained by our previous method.7 
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Scheme 4 
 
The utilization of Yamamoto's racemic acid ester (±)-7 verified the norbornene approach to 
aminoazanoradamantanes, but we were also still faced with the task of producing non-racemic material. In 
addition, several steps in the sequence were low yielding and therefore unsuitable for large scale work.  Our 
preliminary attempts at resolution of 5-norbornene-2,3-dicarboxylic acid  utilizing chiral bases were not 
encouraging.  Zwanenburg's esterase approach11 employing dimethyl 5-norbornene-2,3-dicarboxylate is 
attractive but affords the wrong enantiomer for the production of SC-52491.  We were ultimately attracted to 
the highly efficient asymmetric Diels-Alder reaction reported by Helmchen2c,12  to prepare the requisite 
norbornene to serve as an intermediate for the preparation of chiral aminoazanoradamantanes.  The synthetic 
approach to SC-52491 starting with Helmchen’s Diels-Alder methodology was realized as outlined in Schemes 
5 and 6.   
The chiral norbornene diethyl-(S)-lactate ester 18 was prepared via an uncatalyzed Diels-Alder reaction 
of the corresponding fumarate diethyl-(S)-lactate ester 17 and cyclopentadiene according to Helmchen2c,12 
(Scheme 5).  The original procedure reported the use of carbon tetrachloride/hexane (1:3) for this Diels-Alder 
reaction.  Since we did not want to use halogenated solvents on a large scale, particularly not carbon 
tetrachloride, we examined a number of other solvent systems.  All other solvent systems examined gave 
inferior results (82-90% d.e.), but we found unexpectedly that utilization of triethylamine as a solvent gave the 
desired diastereomer 18 in 91-95% d.e.  The Diels-Alder reaction proceeds smoothly on warming the reaction 
from -25°C to room temperature.  Saponification of 18 and iodolactonization gave the crystalline iodolactone 
(+)-19 in 63% yield from fumaric ester  17 and in 99.3% e.e. by chiral HPLC.  The crystallization of (+)-19 is 
responsible for the very high e.e. beyond what may be expected from the diastereomeric ratio of 18.  The 
carboxylic acid moiety of (+)-19 was then converted to the primary amide (+)-20 via the acid chloride in 81-
96% yield.  A Hofmann-type rearrangement was performed utilizing HTIB (hydroxytosyloxy iodobenzene; 
Koser's reagent13) to give the primary amine (+)-21.  The reaction was driven to completion with the addition of 
iodobenzene diacetate, which presumably gives rise to the formation of HTIB in situ. Subsequent tosylation 
gave the tosylamide (-)-22 in high yield.  The iodolactone was reductively cleaved with zinc in acetic acid in 
almost quantitative yield to give the norbornene carboxylic acid (-)-23. 
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Scheme 5 
 
Ozonolysis of (-)-23 with a reductive workup employing sodium borohydride followed by acidification 
of the crude mixture gave the lactone (+)-24 in quantitative yield (Scheme 6).  This procedure employing the 
free carboxylic acid of (-)-23 to enable direct formation of the lactone was an important factor in obtaining high 
yields in this ozonolysis, in contrast to the poor yield obtained in the conversion of norbornene (±)-14 to diol 
(±)-15.  In addition, the resulting γ-lactone of (+)-24 provided a convenient handle for the incorporation of the 
amine functionality.  Ammonolysis of the lactone gave the primary amide (+)-25.  Reduction with borane gave 
amine 26, which was protected as the tert-butylcarbamate to afford BOC-amine diol (+)-27.  Bis-tosylation of 
the diol was followed directly by removal of the tert-butylcarbamate protecting group with trifluoroacetic acid, 
and subsequent treatment with diisopropylethylamine in acetonitrile gave the tosyl-protected azanoradamantane 
(+)-27 in 96% yield without the need for purification.  Deprotection of the tosylamide proceeded cleanly with 
calcium metal in liquid ammonia.  Calcium was chosen over lithium, which we employed earlier,7 because of its 
safer handling characteristics.  Coupling of the derived chiral aminoazanoradamantane 3 with 4-amino-5-chloro-
2-methoxybenzoic acid utilizing carbonyldiimidazole (CDI) as the coupling reagent gave the desired benzamide 
in 70% yield, without the use of the acetamide protecting group that was employed in the earlier synthesis.7  The 
product of the coupling was sufficiently pure to use after trituration with a minimum amount of ethyl acetate. 
The free base was then converted to the crystalline monohydrochloride salt, SC-52491. 
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Scheme 6 
 
Summary 
                Utilization of Yamamoto’s MAD-catalyzed Diels-Alder methodology provided an initial racemic 
approach to the key aminoazanoradamantane (±)-3. A scalable asymmetric synthesis of the serotonergic 
azanoradamantane SC-52491 from inexpensive starting materials via tosyl-protected azanoradamantane (+)-2 
and chiral amine 3 was then developed employing Helmchen's asymmetric Diels-Alder reaction. In this 
approach the asymmetric Diels-Alder step assembles all four requisite asymmetric centers for SC-52491 with 
the proper relative and absolute stereochemistry.  Halogenated solvents were eliminated and no chromatography 
was required in this 15-step sequence which afforded SC-52491 of high enantiomeric purity (>99% e.e.) and 
12% overall yield.   
 
Experimental Section 
General. All reactions were performed under an atmosphere of argon.  Merck silica gel 60 (230-400 mesh) was 
used for flash chromatography.  Merck Kieselgel 60 F254 DC-Fertigplatten (0.25 mm, Art. 5719) were used for 
TLC.  Melting points were determined on a Thomas-Hoover melting point apparatus and are uncorrected.  1H 
NMR spectra were recorded at 300 MHz.  Noise-decoupled and APT 13C NMR spectra were recorded at 75 
MHz on a General Electric QE-300 spectrometer.  IR spectra were recorded on a Perkin Elmer 685 
spectrophotometer.  MIR refers to multiple internal reflectance spectroscopy.  High-resolution mass spectra 
were recorded on a Finnigan MAT8430 instrument.  Elemental analyses were conducted on a Control 
Equipment CEC240-XA instrument. 
 
 (±)-Methyl 3-[[(phenylmethoxy)carbonyl]amino]-2-bicyclo[2.2.1]hept-5-enecar-boxylate [(±)-8].  To a 
solution of carboxylic acid 79 (1.88 g, 9.58 mmol) and triethylamine (1.65 mL, 1.26 g, 12.5 mmol) in acetone 
(30 mL) at 0°C was added ethyl chloroformate (0.92 mL, 1.0 g, 9.6 mmol) dropwise over several minutes.  
After the addition was complete the solution was stirred for 1h at 0°C.  A solution of sodium azide (1.87 g, 28.7 
mmol) in water (30 mL) was then added and the reaction was stirred for an additional hour at 0°C.  The solution 
was then poured in to ice water and the resulting mixture was extracted with ethyl acetate (4 X 50 mL).  The 
combined organic extracts were washed sequentially with sodium bicarbonate and brine and then dried over 
sodium sulfate.  Concentration gave a residue which was dissolved in dry benzene (50 mL) and heated under 
reflux for 1.5 h.  Benzyl alcohol (2.07 g, 19 mmol) was then added and heating under reflux was continued for 
and additional 2.5 h.  Concentration gave a pale yellow oil which was crystallized from Et2O/hexane to give the 
title compound (±)-8 (2.1 g, 73%) as colorless crystals:  mp 73-76°C; IR (MIR) 3362, 1727, 1688, 1538 cm-1; 1H 
NMR (300 MHz) δ 7.40-7.28 (5H, m), 6.25-6.18 (1H, m), 6.12-6.06 (1H, m), 5.11 (2 H, s), 4.85 (1H, br s), 
3.94-3.84 (1H, m), 3.65 (3H, s), 3.14 (1H, br s), 2.85 (1H, br s), 2.55 (1H, t, J =  4 Hz), 1.65 (1H, d, J = 9.6 Hz), 
1.56 (1H, d, J = 9 Hz); 13C NMR (75 MHz, CDCl3) δ 173.1, 155.7, 136.3, 135.8, 135.4 128.3, 128.0, 127.9, 66.6, 
55.2, 52.4, 51.5, 48.8, 46.6, 44.8.  MS (EI) calcd for C17H19NO4 301; found 301.  Anal calcd for C17H19NO4 C, 
67.76; H, 6.36; N, 4.65.  Found C, 67.59; H, 6.46; N, 4.63. 
 
(±)-Phenylmethyl N-[3-(hydroxymethyl)bicyclo[2.2.1]hept-5-en-2-yl]carbamate [(±)-9].  To a solution of 
methyl ester (±)-8 in dry THF (1 mL) and absolute methanol (0.031 mL, 0.76 mmol) was added a solution of 
lithium borohydride (0.37 mL of a 2M solution in THF, 0.76 mmol) and the solution was stirred for 2 h at rt 
before quenching with 1N HCl (3 mL).  The resulting mixture was extracted with ethyl acetate (3 X 15 mL) and 
the combined extracts were washed sequentially with sodium bicarbonate, water and brine, and then dried over 
sodium sulfate.  Concentration gave a colorless oil which was purified by chromatography on silica gel eluting 
with 50/50 ethyl acetate/hexane to give carbinol (±)-9 (84 mg, 84%) as a colorless oil which crystallized on 
standing:  mp 111-113°C; IR (MIR) 3398, 3250, 1690, 1563 cm-1;  1H NMR (300 MHz, CDCl3) δ 7.40-7.30 (5 
H, m), 6.18-6.08 (2 H, m), 5.37 (1H, br s), 5.11 (1H, d, J = 12 Hz), 5.04 (1 H, d, J = 12 Hz), 4.04 (1H, br s), 
3.62-3.52 (1H, m), 3.23 (1H, t, J = 10 Hz), 3.17-3.10 (1H, m), 2.79 (1H, s) 2.73 (1H, s), 2.03-1.95 (1H, m), 1.57 
(2H, s);  13C NMR (75 MHz, CDCl3) δ 156.9, 136.5, 136.3, 134.9, 128.5, 128.2, 66.8, 65.6, 56.0, 53.1, 48.5, 
46.9, 44.1.  MH+ (CI) calcd for C16H19NO3 274, found 274.  Anal calcd for C16H19NO3.015H2O C, 69.62; H, 7.05; 
N, 5.07.  Found C, 69.81; H, 7.05; N, 5.07. 
 
Mesylate (±)-10  To a solution of alcohol (±)-9 (611 mg, 2.23 mmol), triethylamine (339 mg, 3.35 mmol), and 
DMAP (14 mg, 0.11 mmol) in dry methylene chloride at -78°C was added methanesulfonyl chloride (384 mg, 
3.35 mmol) via syringe.  After 3 d at -30°C the suspension was diluted with additional methylene chloride (40 
mL) and the resulting solution was washed successively with 1 N HCl, water, and brine.  After drying over 
sodium sulfate the solution was concentrated to the desired mesylate (±)-10 as an oil which solidified to a 
colorless powder:  mp 77-80°C; IR (MIR) 3370, 1691, 1528, 1323 cm-1;  1H NMR (300 MHz, CDCl3) δ 7.42-
7.29 (5H, m), 6.22 (1H, dd, J = 5.7, 2.8 Hz), 6.18 (1H, dd, J = 5.7, 2.7 Hz), 5.10 (2H, s), 4.94-4.82 (1H, m), 4.35 
(1H, dd, J = 8.6, 6.1 Hz), 3.91 (1H, t, J = 10 Hz), 3.17-3.08 (1 H, m),  2.98 (4H, br s), 2.78 (1H, s), 2.12 (1H, 
ddt, J = 9.6, 6.4, 3.5 Hz), 1.72 (1H, dd, J = 9, 1.2 Hz), 1.55 (1H, d, J = 9 Hz);  13C NMR (75 MHz, CDCl3) δ 
155.9, 136.4, 136.2, 135.5, 128.5, 128.1, 128.0, 72.1, 66.8, 54.7, 48.8, 48.6, 46.6, 43.2, 37.2.  MS MH+ (CI) 
calcd for C17H21NO5S 352, found 352.  Anal. calcd for C17H21NO5S.1/4H2O C, 57.37; H, 6.09; N, 3.94.  Found 
57.58; H, 6.14; N, 3.84. 
 
(±)-Phenylmethyl N-[3-formylbicyclo[2.2.1]hept-5-en-2-yl]carbamate [(±)-12].  To a solution of alcohol (±)-
9 (404 mg, 1.48 mmol) and triethylamine (450 mg, 4.44 mmol) in dry DMSO (5 mL) was added sulfur trioxide-
pyridine complex (706 mg, 4.44 mmol).  The pale yellow solution was stirred at rt for 15 minutes, then poured 
into ice water (50 mL).  The mixture was extracted with ethyl acetate (3 X 50 mL) and the combined organic 
extracts were washed successively with water (4 X 30 mL) and brine and then dried over sodium sulfate.  
Concentration gave the title aldehyde (±)-12 (380 mg, 95%) as a colorless solid:  mp 75-79°C.  IR (MIR) 3347, 
1705, 1686, 1536 cm-1;  1H NMR (300 MHz, CDCl3), δ 9.59 (1H, s), 7.43-7.29 (5H, m), 6.12 (2H, m), 5.11 (2H, 
s), 4.92 (1H, br s), 3.89-3.80 (1H, m), 3.21-3.17 (1H, m), 2.93-2.85 (1H, m), 2.57 (1H, q, J = 3 Hz), 1.69 (1H, 
dd, J = 8.9, 0.95 Hz), 1.61 (1H, d, J = 8.9 Hz);  13C NMR (125 MHz, CDCl3) δ 202.6, 155.9, 136.2, 135.8, 135.6, 
66.9, 61.4, 53.4, 48.6, 46.7, 43.9.  MS (CI) MH+ calcd for C16H17NO3 272, found 272.  Anal calcd for 
C16H17NO3.0.2H2O C, 69.90; H, 6.38; N. 5.10.  Found C, 70.05; H, 6.68; N, 5.08.  
 
(±)-Phenylmethyl N-[3-(aminomethyl)bicyclo[2.2.1]hept-5-en-2-yl]carbamate [(±)-13].  To a solution of the 
aldehyde (±)-12 (243 mg, 0.89 mmol) in methanol (9 mL) at rt was added ammonium acetate (690 mg, 8.9 
mmol) followed by borane-pyridine (83 mg, 0.89 mmol).  After stirring for 2.5 h at rt the solution was 
concentrated in vacuo to give a residue which was treated with 20% aqueous potassium carbonate (15 mL) and 
extracted with chloroform (3 X 15 mL).  The combined extracts were washed with water and brine and then 
dried over sodium sulfate.  Concentration gave a residue which was chromatographed on silica gel eluting with 
4/96 EtOH(NH3)/ethyl acetate to give the amine (±)-13 (30 mg, 12%) as a colorless glass.  1H NMR (300 MHz, 
CDCl3) δ 7.42-7.28 (5 H, m), 6.20-6.03 (1 H, m), 6.10 (1 H, dd, J = 5.6, 2.7 Hz), 5.09 (2 H, s), 5.05 (1 H, d, J = 
3.3 Hz), 3.12 (1 H, d, J = 5.0 Hz), 2.82 (1 H, br s), 2.74 (1 H, br s), 2.65 (1 H, dd, J = 12, 7.4 Hz), 2.52 (1 H, dd, 
J = 12, 7.6 Hz), 1.67 (1 H, m), 1.63 (1 H, dd, J = 8.8, 1.1 Hz), 1.50 (1 H, d, J = 8.9 Hz), 1.39 (2 H, s). 
 
(±)-1,1-Dimethylethyl N-[3-[[(phenylmethoxy)carbonyl]amino]bicyclo[2.2.1]hept-5-en-2-yl]methylcar-
bamate [(±)-14].  To a solution of the amine (±)-13 (300 mg, 1.10 mmol) in dry THF (30 mL) was added di-
tert-butyldicarbonate (280 mg, 1.28 mmol).  After stirring for 24 h at rt the solution was concentrated in vacuo 
to give a residue which was chromatographed on silica gel eluting with 30/70 ethyl acetate/hexane to afford the 
title BOC-protected amine (±)-14 (359 mg, 88%) as a colorless solid:  mp 116-117°C;  IR (MIR) 3340, 1685, 
1522, 1258 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.40-7.28 (5 H, m), 6.15 (2 H, m), 5.50 (1 H, br s), 5.10 (2 H, s), 
4.89 (1 H, d, J = 5 Hz), 3.24-3.07 (2 H, m), 2.79 (2 H, br s), 2.74 (1 H, s), 1.86 (1 H, br s), 1.63 (1 H, d, J = 9 
Hz), 1.51 (1 H, d, J = 9 Hz), 1.44 (9 H, s).  13C NMR (75 MHz, CDCl3) δ 156.2, 156.1, 136.3, 136.0, 135.3, 
128.5, 128.1, 66.8, 56.0, 50.1, 49.9, 48.8, 46.8, 44.2, 44.0, 28.3.  HRMS M+1 calc for C21H28N2O4 373.2127, 
found 373.2138.  Anal calcd for C21H28N2O4 C, 67.72; H, 7.58; N. 7.52.  Found C, 67.59; H, 7.67; N, 7.41. 
 
(±)-1,1-Dimethylethyl N-[1,4-bis(hydroxymethyl)-3-[[(phenylmethoxy)carbonyl]-amino]cyclopentan-2-yl]-
carbamate [(±)-15].  Ozone was bubbled through a solution of BOC-amine (±)-14 (36 mg, 0.097 mmol) in 5:1 
CH2Cl2/MeOH at -78°C until a blue color persisted (3 min).  Argon was then bubbled through the solution until 
the blue color disappeared.  Sodium borohydride (18 mg, 0.48 mmol) was added to the solution at minus 78°C  
and the reaction was allowed to warm up to rt over 1 h.  After stirring for an additional 16 h at rt, brine (10 mL) 
was added and the reaction was extracted with methylene chloride (4 X 10 mL).  The combined organic extracts 
were washed successively with water and brine and then dried over sodium sulfate.  Concentration gave a 
colorless oil which was purified by preparative thin-layer chromatography on silica gel eluting (2 X) with 4/96 
EtOH/ethyl acetate to give the diol (±)-15 (11 mg, 27%) as colorless crystals:  mp 142-144°C;  IR (MIR) 3288, 
1691, 1667, 1541 cm-1; 1H NMR (CDCl3) δ 7.39-7.27 (5 H, m), 5.57 (1 H, br s), 5.28 (1 H, br s), 5.13 (1H, d, J = 
13 Hz), 5.07 (1 H, d, J = 13 Hz), 3.64 (2 H, m), 3.58-3.48 (2 H, m), 3.48-3.25 (2 H, m), 3.18-3.07 (1 H, m), 2.59 
(1 H, br s), 2.40-2.26 (1 H, m), 2.17-1.76 (4 H, m), 1.43 (9 H, s), 1.28-1.13 (1 H, m); 13C NMR (400 MHz, 
CDCl3) δ 157.3, 156.4, 141.4, 136.4, 128.5, 128.2, 128.1, 105.0, 79.3, 67.1, 63.8, 63.0, 56.3, 50.5, 48.1, 47.7, 
39.5, 39.4, 28.9, 28.5.  MS M+1 calcd for C21H32N2O6, 409.2339; found 409.2364.  Anal. Calcd for 
C21H32N2O6.1/4H2O  C, 61.07; H, 7.93; N, 6.78.  Found C, 61.02; H, 7.67; N, 6.73. 
 
(±)-Phenylmethyl N-(hexahydro-2,5β-methano-1H-3aα,6aα-cyclopenta[c]pyrrol-4α-yl)carbamate [(±)-
16].  To a solution of diol (±)-15 (18 mg, 0.044 mmol) in pyridine (0.6 mL) at 0°C was added solid p-
toluenesulfonyl chloride (45 mg, 0.24 mmol) with stirring.  After dissolution was complete the solution was 
allowed to stand at 0°C for 23 h.  The solution was then poured onto ice (15 g) and extracted with ethyl acetate 
(3 X 10 mL).  The combined organic extracts were washed successively with water (3 X 30 mL) and brine (30 
mL) and then dried over sodium sulfate.  Concentration gave the di-tosylate (23 mg) as a colorless oil which 
was treated directly with freshly-distilled trifluoroacetic acid (0.5 mL) at rt.  After stirring for 15 min the 
solution was concentrated in vacuo to give a residue which was redissolved in acetonitrile (1 mL) and treated 
with diisopropylethylamine (31 mg, 0.24 mmol).  After 21 h at rt the solution was concentrated in vacuo to give 
a residue which was treated with aqueous 15% potassium carbonate (1 mL) and then extracted with chloroform 
(3 X 15 mL).  The combined organic extracts were washed successively with water and brine and then dried 
over sodium sulfate.  Concentration then gave the title azanoradamantane (±)-16 (9.2 mg, 78%) as colorless 
crystals. IR (MIR) 3171, 1703, 1454, 1259, 1247 cm-1;  1H NMR (CDCl3) δ 7.39-7.27 (5 H, m), 5.08 (2 H, s), 
4.71 (1 H, br s), 3.97 (1 H, d, J = 6 Hz), 3.12 (1 H, d, J = 11 Hz), 2.99 (1 H, dd, J = 11, 3 Hz), 2.95-2.68 (4 H, 
m), 2.55-2.40 (2 H, m), 2.08 (1 H, s), 1.98-1.85 (1 H, m), 1.80 (1 H, d, J = 12 Hz);  13C NMR (400 MHz, CDCl3) 
δ 128.6, 128.1, 105.0, 66.7, 65.2, 63.8, 57.6, 45.8, 45.6, 42.6, 38.8, 37.7.  MS calcd for C16H20N2O2: 272.1525; 
found 272.1524. 
 
(±)-2,5β-methano-1H-3aα,6aα-cyclopenta[c]pyrrol-4α-amine [(±)-3] from Cbz-derivative (±)-16.  To a 
suspension of 10% palladium on carbon (2 mg) in ethanol was added a solution of benzyl carbamate (±)-16 (9.2 
mg, 0.034 mmol) in methanol (0.4 mL) at rt.  The suspension was then stirred under an atmosphere of hydrogen 
(1 atm) for 1 h.  Removal of the catalyst by filtration and concentration of the filtrate gave the free amine (±)-3 
(4.2 mg, 89%) as a waxy semisolid which was identical by 1H NMR to material prepared previously.7 
 
bis-Lactate fumarate diester (17).  Fumaryl chloride (100 g, 0.653 mol) and ethyl (S)-lactate (147 mL, 1.3 
mol) were dissolved in 1.6 liters of toluene with 400 mg of hydroquinone. The reaction mixture was heated 
between 80°C and 85°C for 18 h, sweeping the HCl from the mixture with a gentle stream of nitrogen.  The 
reaction mixture was then cooled to -25°C. A second portion of ethyl (S)-lactate was added. Triethylamine  (191 
mL; 1.37 mol) was added to the reaction mixture, keeping the temperature below -10°C. The reaction mixture 
was stirred for one hour, allowing the reaction mixture to warm to room temperature. The reaction mixture was 
washed successively with 2 X 200 mL 2N HCl, 200 mL water, 4 X 200 mL 2N NaOH, then 3 X 250 mL brine. 
The organic layer was dried over MgSO4 and concentrated. The residue was diluted to 1 liter with 15% 
EtOAc/hexane and then filtered through 600 g of silica, eluting with 8 X 500 mL fractions of 15% 
EtOAc/hexane to yield 186 g (90.3%) of the desired diester 17 as an oil, which was used without further 
purification.  1H NMR (CDCl3) δ 7.0 (2H, s), 5.19 (2H, q, J=11 Hz), 4.22 (4H, q, J=12 Hz), 1.57 (6H, d, J=11 
Hz), 1.3 (6H, t, J=12 Hz). 
 
Diels-Alder adduct (18).  In a modification of Helmchen’s2c procedure, di-(ethyl (S)-lactate) fumarate 17 (352 
g, 1.11 mol) was dissolved in 5.5 liters of Et3N and cooled to 0°C. Cyclopentadiene (140 mL; 1.71 mol) was 
added within ten minutes, and the reaction was mildly exothermic. The temperature reached 8°C before 
dropping again to 0°C. The reaction mixture was allowed to warm to room temperature and stir for 18 h.  
Concentration afforded norbornene 18 (450.7 g, 100%) as an oil and used without further purification.  The ratio 
of the two diastereomers was determined by HPLC [Supelco LC-18 DB; 65/35 MeCN/H2O] to be 92.8:7.2 for 
(2R,3R)/(2S,3S). 
 
(+)-Hexahydro-6β-iodo-2-oxo-3αR,5α-methano-2H-3aβ,6aβ cyclopenta[b]furan-7S-carboxylic acid [(+)-
19].  The saponification of diester 18 (471.5 g, 1.17 mol) to give the corresponding diacid was carried out as 
described by Helmchen,2c and conversion of the diacid to the iodolactone (+)-192c was followed with a modified 
workup using  THF/EtOAc (1:1) for the extractions to afford 227.5 g (63% from fumarate 17) of the iodolactone 
(+)-19.  Anal. Calcd for C9H9IO4:  C, 35.09; H, 2.94; I, 41.19.  Found:  C, 35.28; H, 2.92; I, 41.23.  [α]D +54.4° 
(c = 1.0 in EtOH) 
 
(+)-Hexahydro-6β-iodo-2-oxo-3αR,5α-methano-2H-3aβ,6aβ cyclopenta[b]furan-7S-carboxamide [(+)-20].  
Iodolactone (+)-19 (227.5 g, 0.73 mol) was suspended in SOCl2 (132 mL) and gently warmed to reflux, where 
complete solution occurred. The reaction mixture was concentrated to remove the excess SOCl2. The residue 
was dissolved in toluene (350 mL) and slowly added to a mixture of liquid NH3 (85 mL) and 2 liters of THF 
cooled to -30°C.  The reaction mixture was stirred for 0.5 h before adding 500 mL of H2O. The layers were 
separated and the organic layer was washed with brine (500 mL), dried over MgSO4 and concentrated to an oil. 
The oil slowly crystallized when triturated with EtOAc. The solid was filtered and washed with EtOAc and 
dried in vacuum to yield 181.5 g (81%) of primary amide (+)-20 as a white solid:  DSC 165.65°C;  [α]D +34.5° 
(c = 1.0 in EtOH);  IR (KBr) 3470, 3423, 3362, 3187, 1769, 1681 cm-1;  1H NMR (400 MHz, CDCl3) δ 5.62 (1H, 
br s), 5.45 (1 H, br s), 5.14 (1 H, d, J = 5.0 Hz), 3.87 (1 H, d, J = 2.6 Hz), 3.21 (1 H, m), 3.07 (1 H, dd, J = 4.8 
Hz, 1.1 Hz), 2.93 (1 H, s), 2.69 (1 H, s), 2.33 (1 H, dd, J = 11.9, 1.3 Hz), 2.24 (1 H, dd, J = 11.9, 2.1 Hz); 13C 
NMR (400 MHz, d6-DMSO) δ 177.9, 171.2, 88.8, 51.2, 51.0, 46.1, 41.5, 35.2, 35.1, 28.1.  Anal. Calcd for 
C9H10INO3:  C, 35.20; H, 3.28; I, 41.32; N, 4.56.  Found:  C, 35.40; H, 3.26; I, 41.20; N, 4.50. 
 
(+)-Hexahydro-6β-iodo-2-oxo-3αR,5α-methano-2H-3aβ,6aβ-cyclopenta[b]furan-7S-amine, 4-methyl-
benzenesulfonate [(+)-21].  Primary amide (+)-20 (30.0 g, 96.0 mmol) was dissolved in CH3CN (500 mL). 
HTIB (hydroxy(tosyloxy)iodobenzene, 42 g, 0.108 mol) was added to the reaction mixture and stirring was 
continued. The mixture thickened to a solid mass within 5 minutes. The mixture was slowly warmed to reflux 
where the solid mass became mobile again. The reaction mixture was allowed to cool to 35°C. IBDA 
(iodobenzene diacetate, 15.4 g, 48 mmol) was added and the mixture thickened again. The mixture was reheated 
to 65°C where the solid mass became mobile again. The reaction mixture was stirred 18 h, filtered, washed with 
CH3CN and suction dried to yield 35.4 g (82%) of primary amine (+)-21: [α]D +32.8 (c= 1.09, EtOH); [α]365 
+137.5 (c= 1.09, EtOH);  IR (KBr) 3470, 3361, 1767, 1682 cm-1;  1H NMR (400 MHz, CDCl3) δ 5.13 (1H, d, J= 
2 Hz); 3.88 (1H, d, J= 1 Hz); 3.21 (1H,t, J=1 Hz); 3.07 (1H, d, J=1.5 Hz); 2.93 (1H, s); 2.49 (1H, s); 2.33 (1H, 
d, J=4 Hz); 2.22 (1H, d, J= 4 Hz); 13C NMR (400 MHz, CDCl3) δ 177.8, 171.2, 88.8, 51.2, 51.0, 41.5, 35.1, 28.1. 
Anal. Calcd for C15H18INO5S:  C, 39.92; H, 4.02; N, 3.10; S, 7.11.  Found:  C, 39.96; H, 4.04; N, 2.90; S, 7.38.   
For the monotosylate salt: [a]D +30.0 (c= 1.04, EtOH);  [a]365 +98.6 (c= 1.04, EtOH); IR(KBr) 3435, 2997, 1792 
cm
-1;  1H NMR (400 MHz, d6-DMSO) δ 7.49 (2H, d, J= 4 Hz); 7.12 (2H, d, J= 4 Hz); 5.16 (1H, d, J= 3 Hz); 5.12 
(1H, d, J= 2 Hz); 4.11 (1H, d, J= 1 Hz); 3.66 (1H, s); 3.30 (1H, t, J=1 Hz); 2.76 (1H, s); 2.62 (1H, d, J=2Hz); 
2.30 (3H, s); 2.29 (1H, d, J= 7 Hz); 2.12 (1H, d, J= 7 Hz).  13C NMR (400 MHz, d6-DMSO) δ 175.0, 145.6, 
137.5, 128.0, 125.4, 87.3, 53.1, 50.8, 45.9, 44.0, 32.9, 24.9, 20.7.  
 
(-)-N-(3aβ,6aβ-hexahydro-6β-iodo-2-oxo-3αR,5α-methano-2H-cyclopenta[b]furan-7S-yl)-4-methylben-
zenesulfonamide [(-)-22].  The tosylate salt of  (+)-21 (1.0 g, 2.2 mmol) was dissolved in pyridine (5.0 mL).  p-
Toluenesulfonyl chloride (476 mg, 2.5 mmol) was added and the reaction mixture stirred for 2 h and 
concentrated. The residue was partitioned between THF and brine. The organic layer was washed subsequently 
with dilute HCl and dilute K2CO3, and dried over MgSO4, and concentrated. The residue was placed on 50 g of 
silica and eluted with 50 mL of 1:1 EtOAc/heptane. The solution was concentrated to an oil which slowly 
crystallized to yield 913 mg (95%) of tosylamide (-)-22. [α]D -65.6° (c = 1.0 in EtOH); IR (KBr) 3433, 3238, 
1763 cm-1;  1H NMR (400 MHz, CDCl3) δ 7.79 (2H, d, J= 4 Hz); 7.73 (2H, d, J= 4 Hz); 5.16 (1H, d, J= 3 Hz); 
5.04 (1H, d, J= 2 Hz); 3.49 (1H, d, J= 1 Hz); 3.12 (1H, t, J=1 Hz, J= 3 Hz); 2.72 (1H, s); 2.43 (3H, s); 2.31 (1H, 
d, J= 7 Hz); 2.11 (1H, d, J= 7 Hz).  13C NMR (400 MHz, CDCl3) δ 175.38, 144.4, 136.1, 130.2, 127.3, 87.8, 
58.0, 53.4, 47.3, 45.7, 34.6, 24.9, 21.6. Anal. Calcd for C15H16INO4S:  C, 41.58; H, 3.72; N, 3.23; S, 7.40.  
Found:  C, 41.49; H, 3.79; N, 3.28; S, 7.77. 
 
(-)-3R-[[(4-Methylphenyl)sulfonyl]amino]-bicyclo[2.2.1]hept-5-ene-2αR carboxylic acid [(-)-23].  
Iodolactone (-)-22 (27.0 g, 0.062 mol) and Zn° (16.2 g, 0.249 mol) were combined in glacial acetic acid (100 
mL) and refluxed for 0.5 h. The reaction mixture was cooled and filtered through celite. The filtrate was 
concentrated and the residue suspended in water, and the resulting crystalline solid was filtered, washed with 
water and dried to yield 18.4 g (97%) of carboxylic acid (-)-23 as a white solid. [α]D -24.9° (c= 1.0, EtOH);  
[α]365 -46.8° (c= 1.0, EtOH);  IR(KBr) 3921, 3788, 1707 cm-1;  1H NMR (300 MHz, d6-DMSO) δ 7.85 (2H, d, J= 
4 Hz); 7.69 (2H, d, J= 4 Hz); 6.08-5.94 (2H, m, J= 2 Hz); 3.39 (1H, s); 3.24 - 3.30 (1H, m); 2.76 (1H, s); 2.99 
(1H, s); 2.61 (1H, t, J=2 Hz) 2.30 (3H, s); 2.58 (1H, s); 2.48 (3H, s); 1.72 (1H, d, J=2 Hz); 1.40 (1H, d, J=2 Hz).  
13C NMR (300 MHz, d6-DMSO) δ 173.4, 142.4, 138.3, 135.7, 135.4, 129.4, 126.5, 56.1, 50.9, 48.4, 46.5, 44.6, 
20.9.  Anal. Calcd for C15H17NSO4:  C, 56.95; H, 5.73; N, 4.43; S, 10.14.  Found:  C, 57.08; H, 5.42; N, 4.36; S, 
10.33. 
 
(+)-N-(5aS-hydroxymethyl-3-oxo-3aα,6aα-cyclopenta[c]furan-4βR-yl)-4-methylbenzene-sulfonamide  
[(+)-24].   
Ozone was bubbled through a solution of carboxylic acid (-)-23 (2.0 g, 6.5 mmol) in ethyl acetate/methanol (24 
mL; 5:1) at -78°C until a light blue color persisted.  Caution should be exercised when utilizing ozone in 
flammable solvents to avoid fire.  After stirring for an additional 0.5 h at -78°C, argon was bubbled through the 
solution for 25 min to remove excess ozone.  To the colorless solution was then added sodium borohydride 
pellets (1.07 g, 32.5 mmol) at -78°C.  The reaction mixture allowed to warm to room temperature and stirred for 
40 h.  To the reaction mixture was added 3 drops of methyl orange/methanol indicator followed by a solution of 
2N HCl/methanol to give a light pink color and the reaction was then stirred for 72 h at room temperature.  The 
mixture was concentrated in vacuo.  To the residue was added brine (35 mL) and the mixture was extracted with 
ethyl acetate (3 x 50 mL).  The combined extracts were washed successively with water and brine, dried over 
MgSO4, filtered and concentrated to give the desired lactone (+)-24 as a waxy white solid (2.01 g, 100%):  [α]D 
= +1.4°  (c = 0.70 in CH3OH);  IR (MIR) 3453, 3219, 1753, 1156 cm-1;  1H NMR (CD3OD) δ 7.82 (2H, d, J = 8 
Hz), 7.34 (2H, d, J = 8 Hz), 4.27 (1H, dd, J = 9, 6 Hz),  4.06 (1H, d, J = 9 Hz); 3.68 (1H, dd, J = 7, 3 Hz), 3.50 
(1H, dd, J = 10, 4 Hz),  3.36 (1H, dd, J = 11, 6 Hz), 2.97 (1H, m), 2.78 (1H,   dd, J = 9, 3 Hz),  2.40 (3H, s); 2.09 
(2H, m), 1.25 (1H, m);  13C (CD3OD) δ 178.4, 142.8, 138.5, 128.8, 126.6, 70.8, 60.8, 57.8, 46.9, 46.6, 38.9, 32.2, 
19.7. 
 
(+)-1a,4a-bis(hydroxymethyl)-3b-[[(4-methylphenyl)sulfonyl]amino] cyclopentane-2a-carboxamide (25).  
A solution of lactone 24 (2.0 g, 6.5 mmol) in methanol in a Parr Shaker was pressurized with ammonia gas to 
50 psi for 4 h at 60°C.  The solution was then filtered through celite and concentrated in vacuo to give a white 
solid.  The solid was recrystallized from ethanol to give primary amide 25 (1.52 g, 72%):  mp = 191.5 - 
192.5°C;  [α]D = +46.8°  (c = 1.10 in CH3OH);  IR (MIR) 3453, 3219, 1753, 1156 cm-1;  1H NMR (300 MHz, 
CD3OD) δ 7.70 (2H, d, J = 7.5 Hz) 7.33 (2H, d, 7.5 Hz) 3.66 (3H, m), 3.66 (1H, dd, J = 6.0, 2.0 Hz)  3.42 (1H, 
dd, J = 7.5, 2.5 Hz),  2.70 (1H, m), 2.42 (3H, s), 2.41 (1H, m), 2.37 (1H, m), 1.99 (1H, m), 1.25 (1H, m); 13C 
(100.6 MHz, CD3OD) δ 177.6, 144.6, 139.5, 130.7, 120.2, 64.3, 64.0, 60.0, 54.8, 50.0, 44.5, 33.0, 21.5;  Anal. 
Calcd for C15H22N2SO5.0.5 H2O:  C, 51.27; H, 6.60; N, 7.97.  Found:  C, 51.16; H, 6.53; N, 7.96.   
 
Amine 26. To a suspension of primary amide 25 (1.0 g, 2.9 mmol) in THF (100 mL) was added dropwise a 1M 
solution of borane-THF over 20 min.  The reaction mixture stirred for 1 h at rt followed by refluxing for 18 h.  
The reaction mixture was cooled to 0°C and 15% aqueous HCl (100 mL) was added.  The reaction was then 
allowed to warm up to stir at rt for 14 h  The solution was then concentrated in vacuo to a white foam which 
was dissolved in water (10 mL) and then treated with 1N NaOH (10 mL).  The solution was stirred for 3 h, 
saturated with NaCl, and extracted with THF.  The combined extracts were dried over MgSO4 and then 
concentrated in vacuo to give oil.  The oil was passed through a pad of silica eluting with ethyl acetate followed 
by 20% CH3OH(NH3)/THF to give the free amine 26 (700 mg, 74%):     1H (300 MHz, CD3OD) δ 7.76 (2H, d, J 
= 9.0 Hz), 7.38 (2H, d, J = 9.0 Hz), 3.48 (2H, m), 3.26 (1H, d, J = 4 Hz), 3.05 (2 H, m), 2.72 (2H, d, J = 4 Hz),  
2.41 (2H, s), 2.31 (1H, m), 1.12 (1H, m), 1.84 (1H, m), 1.96 (2H, m);  13C (100.6 MHz, CD3OD) δ 143.7, 139.5, 
129.8, 127.0, 62.8, 62.7, 58.3, 49.9, 40.0, 39.2, 29.6, 20.6.  This amine was protected directly as the BOC 
derivative without further purification. 
 
(+)-1,1-dimethylethyl-N-[[1α,4α-bis(hydroxymethyl)-3β-[[(4-methylphenyl)sulfonyl]amino]-cyclopentan-
2α-yl]methyl]carbamate (27). Thus, to a solution of the amine 26 (570 mg, 1.73 mmol) and triethyl amine 
(0.45 mL, 1.9 mmol) in acetone/water (10 mL) was added BOC-ON (2-(tert-butoxycarbonyloxyimino)-2-
phenylacetonitrile; 470 mg, 2.9 mmol) and the reaction stirred for 18 h at rt.  The solution was extracted with 
ethyl acetate (3X).  The combined extracts were washed successively with water and brine, dried over MgSO4, 
filtered, and concentrated in vacuo to an oil.  The oil was passed through a pad of silica gel eluting with ethyl 
acetate to give the BOC-protected amine 27 (740 mg, 100%).  [α]D +22.4  (c = 0.157, CHCl3); IR (MIR) 3384, 
3291, 1684 (str), 1516, 1156 cm-1;  1H NMR (300 Hz, CD3OD) δ  7.77 (2H, d, J = 8.0 Hz)  7.37 (2H, d, J = 8.0 
Hz), 3.49 (2H, m), 3.35 (2H, m), 3.19 (1H, m), 3.12 (1H, t, J= 7.5 Hz), 2.92 (2H, m), 2.24 (1H, m), 2.41 (3H, s), 
1.92 (1H, m), 2.04 (1H, m), 1.42 (9H, s);  13C NMR δ (100.6 Hz, CD3OD) 143.6, 139.5, 129.7, 127.1, 78.5, 63.1, 
62.4, 58.6, 48.4, 40.7, 38.5, 29.7, 27.8, 20.5.  Anal Calcd for C20H32N2SO6:1/2 H2O: C, 54.90; H, 7.60; N, 6.40.  
Found: C, 54.91; H, 7.47; N, 6.07. 
 
(+)-N-(hexahydro-2,5β-methano-1H-3aS,3aα,6aα-cyclopenta[c]pyrrol-4α-yl)-4-methyl-benzenesulfon-
amide [(+)-2].  To a solution of BOC-amine diol (+)-27 (207 mg, 0.484 mmol) in dry pyridine (2.4 mL) at  
20°C was added p-toluenesulfonyl chloride (369 mg, 1.94 mmol) with stirring.  After dissolution was complete 
the solution was allowed to stand at 0°C for 21 h.  The reaction was then poured onto ice and extracted with 
ethyl acetate (3X).  The combined extracts were washed successively with water (5X) and brine and then dried 
over sodium sulfate.  Concentration gave a colorless foam (357 mg).  The foam was dissolved in trifluoroacetic 
acid (5 mL) and allowed to stand for 15 min at rt after which time the reaction was concentrated under vacuum.  
The resulting residue was dissolved in acetonitrile (10 mL) and treated with diisopropylethylamine (433 mg, 
3.35 mmol).  After 4 days at rt the pale yellow solution was warmed to 46°C for 2h.  Concentration gave a 
residue which was treated with 4N KOH/presaturated with NaCl (5 mL) and extracted with ethyl acetate (5X).  
The combined extracts were washed with water (2X) and brine and dried over sodium sulfate.  Concentration 
then gave the tosylamide azanoradamantane (+)-2 (134 mg, 96%) as a pale yellow solid:  mp 203-205°C; [α]D = 
+3.0° (c = 0.76 in CHCl3).  The proton NMR was identical to the material prepared via the previously described 
route.7 
 
Hexahydro-2,5β-methano-1H-3aS,3aα,6aα-cyclopehta[c]pyrrol-4α-amine (3).  To liquid ammonia (30 mL) 
at -33°C was added a solution of tosylamide (+)-2 (539 mg, 1.84 mmol) in THF (7 mL).  Calcium metal (319 
mg, 7.96 mmol) was added in three portions over 5 min.  After 30 min the dark blue reaction was quenched with 
addition of solid ammonium chloride (985 mg, 18.4 mmol).  Concentration gave a residue which was treated 
with 4N KOH-presaturated with NaCl (9.2 mL).  The suspension was filtered through celite and the solid was 
washed with THF.  The filtrate was extracted with THF (7X) and the combined THF rinses and extracts were 
dried over sodium sulfate.  Concentration gave chiral aminoazanoradamantane 3 (0.29 g, 100%) as a colorless 
waxy solid. The proton NMR was identical to the material prepared via the previously described route.7 
 
(+)-4-amino-5-chloro-N-(hexahydro-2,5β-methano-1H-3aS,3aα,6aα-cyclopenta[c]-pyrrol-4α-yl)-2-
methoxybenzamide, (free base of SC-52491).  To a solution of 4-amino-5-chloro-2-methoxybenzoic acid (371 
mg, 1.84 mmol) in DMF (1.8 mL) was added carbonyldiimidazole (298 mg, 1.84 mmol).  After 1 h at rt a 
solution of the chiral aminoazanoradamantane 3 derived from (+)-2 (255 mg, 1.84 mmol) in DMF (1.9 mL) was 
added and the resulting pale yellow solution was stirred at rt for 24 h.  Concentration under vacuum at 36°C 
gave a yellow solid which was triturated with ethyl acetate (5 mL), filtered, and rinsed with cold (0°C) ethyl 
acetate (1.5 mL).  The solid was then dried in vacuo at 52°C to give the free base of SC-58241 as a pale yellow 
solid (413 mg, 70%), which was converted directly to the hydrochloride salt. 
 
(+)-4-amino-5-chloro-N-(hexahydro-2,5β-methano-1H-3aS,3aα,6aα-cyclopenta[c]-pyrrol-4α-yl)-2-
methoxybenzamide, monohydrochloride (SC-52491).  To a solution of free base of SC-52491 (343 mg, 1.04 
mmol) in 95% ethanol (10 mL) was added ethanolic HCl [prepared from acetyl chloride (75 mg, 1.07 mmol) 
and 95% ethanol (0.5 mL)].  The  solution was allowed to stand at 0°C for 24 h.  Filtration of the resulting 
crystalline solid and rinsing with cold (0°C) 95% ethanol (1.5 mL) gave the desired material which was dried at 
63°C in vacuo for 16 h to afford the hydrochloride SC-52491 (337 mg, 88%) as an off-white powder. [α]D = 
+7.1° (c = 0.23, MeOH).  Anal. Calcd for C16H20N3O2Cl.HCl.H2O:  C, 51.07; H, 6.16; N, 11.17; Cl, 18.84.  
Found:  C, 50.80; H, 6.16; N, 11.00; Cl, 18.54. The proton NMR was identical to the material prepared via the 
previously described route.7 
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